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BACKGROUND: End-of-life discussions are associated
with decreased use of life-sustaining treatments in patients
dying of cancer in the outpatient setting, but little is known
about discussions that take place during terminal
hospitalizations.
OBJECTIVES: To determine the proportion of patients
assessed by the clinical team to have decisional capacity
on admission, how many of these patients participated or
had a surrogate participate in a discussion about end-of-life
care, and whether patient participation was associated with
treatments received.
DESIGN: Retrospective review.
SETTING: Inpatient.
PATIENTS: Adult patients with advanced cancer who died
in the hospital between January 1, 2004 and December 31,
2007.
RESULTS: Of the 145 inpatients meeting inclusion criteria,
115 patients (79%) were documented to have decisional
capacity on admission. Among these patients, 46 (40%)
were documented to lose decisional capacity prior to an
end-of-life discussion and had the discussion held instead
by a surrogate. Patients who had surrogate participation in
the end-of-life discussions were more likely to receive
mechanical ventilation (56.5% vs 23.2%, P < 0.01), artificial
nutrition (45.7% vs 25.0%, P ¼ 0.03), chemotherapy (39.1%
vs 5.4%, P <0.01), and intensive care unit (ICU) treatment
(56.5% vs 23.2%, P <0.01) compared to patients who
participated in discussions. There was no difference
between palliative treatments received.
CONCLUSION: The majority of patients with advanced
cancer are considered to have decisional capacity at the
time of their terminal hospitalization. Many lose decisional
capacity before having an end-of-life discussion and have
surrogate decision-makers participate in these discussions.
These patients received more aggressive life-sustaining
treatments prior to death and represent a missed
opportunity to improve end-of-life care. Journal of Hospital
Medicine 2013;8:334–340 VC 2012 Society of Hospital
Medicine
Most patients prefer to die at home, pain free and
without the use of life-sustaining treatments1,2 yet the
majority of patients with serious illness die in the
hospital.3–5 When hospitalized patient die, the care is
frequently focused on life-sustaining treatments6; pain,
dyspnea, and agitation levels are higher when
compared with patients who die in non-hospital set-
tings.7–9 End-of-life discussions and their products (ie,
advanced directives) can clarify treatment options
with patients and family,10 and help ensure that
patients receive care consistent with their beliefs.11–13
End-of-life discussions are associated with a decrease
use of life-sustaining treatments, improved quality of
life, and reduced costs of care.14,15 For the majority of
patients dying of cancer, the first end-of-life discussion
takes place in the hospital setting.16
Conducting end-of-life conversations in the hospital
setting can be challenging. Patients are acutely ill and
nearly 40% are incapable of making their own medical
decisions.17 In order to participate in an end-of-life dis-
cussion, a physician must determine that a patient
meets the 4 criteria of decisional capacity as outlined
by Appelbaum and Grisso:18 Does the patient (1) com-
municate a clear and consistent choice; (2) understand
the relevant information surrounding that decision; (3)
appreciate the consequences of that decision; and (4)
communicate reasoning for that decision?19 In practice,
however, clinicians inaccurately assign capacity up to
25% of the time.17 When a physician determines, accu-
rately or inaccurately, that the patient does not meet
this standard for decisional capacity, discussions must
be held instead with a surrogate decision-maker. Surro-
gate decision-making can make communication with
the physician more difficult,20 delay important medical
decisions,21 and be stressful on the decision-maker.22
To our knowledge, no studies have examined patient
and surrogate participation in end-of-life discussions at
*Address for correspondence and reprint requests: Mark C. Zaros,
MD, Harborview Medical Center, Mailbox 359780, 325 Ninth Ave, Seattle,
WA 98104-2499; Telephone: 206-744-2054; Fax: 206-744-6063;
E-mail: mzaros@uw.edu
Additional Supporting Information may be found in the online version of
this article.
Received: February 4, 2012; Revised: August 24, 2012; Accepted:
September 19, 2012
2012 Society of Hospital Medicine DOI 10.1002/jhm.1989
Published online in Wiley Online Library (Wileyonlinelibrary.com).
334 An Official Publication of the Society of Hospital Medicine Journal of Hospital Medicine Vol 8 | No 6 | June 2013
the time of terminal hospitalization and its association
with end-of-life treatments received.
Our goals were to examine physician assessment of
decisional capacity and the prevalence of end-of-life dis-
cussions during the terminal hospitalization of patients
with advanced cancer. Our research questions were: (1)
What proportion of patients were assessed to have deci-
sional capacity by the clinical team at the time of their
terminal hospital admission? (2) What proportion of
these patients had a documented discussion about end-
of-life care with the clinical team, and for what propor-
tion was the conversation held instead by the patient’s
surrogate decision-maker because the patient was consid-
ered to have lost decisional capacity? (3) Was patient par-
ticipation in a discussion about end-of-life care associated
with life-sustaining and palliative treatments received?
METHODS
Design
This is a retrospective cohort study of consecutive
adult patients with advanced cancer who died at the
University of Michigan Hospital, Ann Arbor, MI,
from January 1, 2004 through December 31, 2007.
This study was exempted from review by the Univer-
sity of Michigan (UM) Institutional Review Board
because decedent data were used.
Sample
The UM Cancer Registry is a database of all cancer
patients treated at the UM Comprehensive Cancer
Center. We used the Registry to identify patients who
met the following criteria: (1) age 18 years at time of
cancer diagnosis; (2) estimated probability of 5-year
survival 20% at time of diagnosis, as predicted by the
SEER Cancer Statistics Review23; (3) the entirety of
cancer treatment was received at University of Michi-
gan Health System (UMHS); and (4) the patient died
while admitted to the University Hospital between
January 1, 2004 and December 31, 2007.
UMHS is a healthcare system and academic medical
center consisting of hospitals, health centers, and clin-
ics, including the University of Michigan Hospital and
Comprehensive Cancer Center. Over 4000 cancer
patients are admitted to University Hospital and
80,000 outpatient visits occur to the Cancer Center
every year. It serves as a major cancer referral center
for the patients of Michigan and the greater Midwest.
The University of Michigan implemented a palliative
care consult service that was started in 2005, during
the time period of our study.
Data Collection
Data were abstracted by review of the medical record
by an internist (M.Z.) using a comprehensive chart
abstraction instrument based on a previously validated
tool.24 Demographic data abstracted from the medical
record included age, religious affiliation, race,
ethnicity, and marital status. The original abstraction
tool, which included 83 items, was reduced to include
47 items focusing on information related to advanced
care planning, hospital course, and end-of-life discus-
sions. Specific items included: reasons for admission,
primary hospital service, occurrence and timing of
end-of-life decision-making, whether patient or family
preferences were elicited through an end-of-life discus-
sion, clinician’s assessment of patient’s decisional
capacity at time of admission and end-of-life conver-
sations, whether a comfort care plan was made, and
whether palliative morphine was used.
The chart abstraction tool was pilot tested on the
medical records of 10 patients, who were not included
in the study, and refined to improve completeness of
data collection. A copy of the abstraction tool is
available upon request.
Definition of Key Variables
Decisional Capacity Assessment
Decisional capacity assessment is a reflection of the
clinical team’s assessment of the patient’s decisional
capacity on admission, and was determined through
examination of the medical record in the first 24 hours
of admission. Positive decision-making capacity assess-
ment was assumed if the clinician assessment of
decisional capacity was documented in the mental
status exam, or if the clinician documented conversa-
tions between clinician and patient in the history that
suggested intact decision-making capacity (ie, clinician
documented terms such as ‘‘patient stated. . .’’ or
‘‘patient described. . .’’ and then described a coherent
or sensible statement which implied patient capacity
and intact mental status), or if the clinician’s documen-
tation of the assessment and plan stated or suggested
decisions were being made by the patient. Other sup-
portive information from the record was used to
corroborate the evidence used to determine the clini-
cian’s assessment of the patient’s decisional capacity,
including whether the patient signed consent forms.
End-of-Life Discussions
The presence of an end-of-life discussion was presumed
when the clinician documented a ‘‘discussion with the
patient,’’ ‘‘discussion with family,’’ or ‘‘family meeting’’
concerning treatment preferences, or when the clinician
quoted the patient’s preferences in a fashion that docu-
ments a face-to-face discussion or directly described the
elicitation of preferences from the patient or family.
Living Will
A living will was identified as present if the document
was scanned into the patient’s medical record, or if
the chart indicated that the patient or family stated
that the patient had completed a living will.
Health Care Proxy
Health Care Proxy or Durable Power of Attorney for
Healthcare was identified as present if the document
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was scanned into the patient’s medical record, or if
the chart indicated that the patient or family stated
that the patient had completed such a document.
Do Not Resuscitate (DNR) on Admission
DNR status was identified as present if the patient
had documents with established DNR orders, or if a
physician explicitly documented code status as DNR
in the admission note or other documents placed in
the record within the first 24 hours of admission.
Intensive Care Unit (ICU)Treatment
Patients were defined as having received ICU treat-
ment if they were admitted directly or subsequently
transferred to the ICU during the hospital course.
Comfort Care
Comfort care was defined as present only if the
phrases ‘‘comfort care,’’ ‘‘palliative care,’’ or ‘‘sup-
portive care,’’ were documented.
Palliative Opioid Therapy
Treatments with morphine or other opioids were
recorded as palliative only if it was explicitly stated
that these medications were used in the context of
palliative or end-of-life care.
Data Analysis
We report the proportion of patients who were docu-
mented to lack decisional capacity at the time of
hospital admission. We compared patient characteris-
tics for those with and without documentation of
decisional capacity on admission, and patients with
decisional capacity on admission who did and did not
participate in discussions about end-of-life care using
chi-square tests for categorical data, t tests for nor-
mally distributed continuous variables, and Mann–
Whitney U tests for non-normally distributed continu-
ous variables. We examined whether documentation
of a discussion about end-of-life care was associated
with life-sustaining and palliative treatments received
using chi-square for categorical treatments, and
Mann–Whitney U tests for days from admission to
initiation of comfort care. We used P < 0.05 to
signify statistical significance.
RESULTS
Characteristics of Population and Decisional
Capacity on Admission
The characteristics of the 145 patients who met entry
criteria are summarized in Table 1. The most common
types of cancers were lung cancer and leukemia/lym-
phoma. Of the 145 patients, the medical team’s
assessment of the patient’s decisional capacity on
admission could be established for 142 patients. As
documented within the first 24 hours of admission, 27
patients (19%) were considered not to have decisional
capacity, and 115 patients (79%) were considered to
have decisional capacity. Both of these groups had
similar age and gender distributions. There were no
significant differences in the distribution of cancer
type between those with and without decisional
capacity. In both groups, the majority of the cancer
diagnoses were made prior to admission. There was
no difference in DNR orders established prior to or
on admission between the groups (Table 1).
End-of-Life Discussion in Patients With Decisional
Capacity on Admission
Of the 115 patients assessed to have intact decisional
capacity on admission, 56 (48.7%) participated in an
end-of-life discussion with the medical team during
their terminal hospitalization. For the remaining 59
patients who did not participate in an end-of-life dis-
cussion during the terminal hospital course, 46
(40.0%) had documentation suggesting they lost deci-
sional capacity prior to a conversation and that the
end-of-life discussions were held instead with the
patient’s surrogate decision-maker, and 13 (11.3%)
had no evidence of any end-of-life discussion (with
the patient or surrogate).
When comparing those patients who participated
in an end-of-life discussion with those patients
whose surrogate participated in the discussion, there
were no significant differences in gender and age
distributions (Table 2). There was a significant dif-
ference in the type of cancers between the 2 groups.
Among patients who participated in their end-of-life
discussions, bone marrow cancer was proportion-
ately more prevalent (17.9% vs 2.2%; P <0.01) and
TABLE 1. Characteristics of Patients With and
Without Documented Decision-Making Capacity
Decision-Making Capacity on
Admission*
No (N ¼ 27) Yes (N ¼ 115)
N (%) N (%) P Value
Age >65 15 (55.6) 60 (52.2) 0.75
Gender (male) 14 (51.9) 68 (59.1) 0.46
Cancer type
Lung 12 (44.4) 42 (36.5) 0.67
Bone marrow 5 (18.5) 35 (30.4)
Liver 3 (11.1) 6 (5.2)
Pancreas 3 (11.1) 7 (6.10)
Esophagus 1 (3.7) 8 (7.0)
Colon 1 (3.7) 6 (5.2)
Other† 2 (7.4) 11 (9.6)
Prior to admission
Cancer diagnosis known 23 (85.2) 91 (79.1) 0.48
Living will completed 6 (22.2) 26 (22.6 0.97
Health care proxy established 3 (11.1) 26 (22.6) 0.18
DNR established 8 (29.6) 27 (23.5) 0.79
Abbreviations: DNR, do not resuscitate.
* Decisional capacity as assessed and documented by the clinician; clinicians assessment of decisional
capacity could not be determined in 3 patients.
†Other cancer types: rectal, stomach, bone sarcoma, renal cell, laryngeal, renal pelvic.
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lung cancer was less prevalent (16.1% vs 41.3%; P
<0.01), when compared to those who required sur-
rogate participation. Timing of cancer diagnosis and
prevalence of advance directives were similar
between the 2 groups. The proportion of patients
who had an established DNR order prior to admis-
sion was higher among those who did participate in
end-of-life discussions when compared to those who
had surrogate participation in these discussions
(30.4% vs 17.4%; P < 0.04).
Life-Prolonging and Palliative Care Treatments Received and
Participation in End-of-Life Discussions
Life-prolonging treatments were more likely to be
used for patients whose end-of-life discussions were
held by patient’s surrogate decision-maker, in compar-
ison to those patients who participated in the discus-
sions themselves. Patients who had conversations held
by surrogates were more likely to receive ventilator
support (56.5% vs 23.2%, P < 0.01), chemotherapy
(39.1% vs 5.4%, P < 0.01), artificial nutrition or
hydration (45.7% vs 25.0%, P ¼ 0.03), and antibiot-
ics (97.8% vs 78.6%, P < 0.01), when compared to
patients who participated in their own end-of-life dis-
cussion. Intensive care treatment rates also differed
significantly between the 2 groups; 56.5% of those
who did not participate in end-of-life discussions, and
only 23.2% of those patients who did participate,
were admitted or transferred to the intensive care unit
(P < 0.01). There was no significant difference in the
proportion of patients who received cardiopulmonary
resuscitation (CPR) (15.2% vs 7.1%, P ¼ 0.56)
(Table 3). Patients who lost decisional capacity and
required a surrogate decision-maker to participate in
their end-of-life discussions had longer length of stay
(15.8 vs 10.3 days, P ¼ 0.03) and length of time to
end-of-life discussions (14.0 vs 6.1 days, P < 0.01)
(Table 3).
A comparison of the proportion of patients receiving
palliative treatments, such as palliative comfort care
orders and morphine infusions, revealed no significant
differences between those with and without a discus-
sion about end-of-life care (Table 3). Furthermore,
while the time interval from hospital admission to ini-
tiation of comfort care was shorter for those who did
participate in end-of-life discussions compared with
those had surrogate participation (9.3 vs 23.5 days,
P ¼ 0.13 for equality), this difference was not statisti-
cally significant (Table 3).
Since a higher proportion of those who partici-
pated in end-of-life discussions during the hospitali-
zation were admitted with a DNR order established
prior to or on admission, we also examined the use
of life-prolonging treatments in the subgroup of
TABLE 2. Among Patients With Documented
Decision-Making Capacity on Admission, the
Characteristics of Patients by Status of Their
Participation in End-of-Life Discussions
Patients With Documented
Decision-Making
Capacity on Admission (N ¼ 115)
N ¼13 N ¼ 102
End-of-Life
discussion
not documented
End-of-Life
discussion
with surrogate
(N ¼ 46)
End-of-Life
discussion
with patient
(N ¼ 56)
N (%) N (%) N (%) P Value
Age 65 9 (69.2) 18 (39.1) 27 (48.2) 0.36
Gender (male) 10 (76.9) 27 (60.0) 31 (55.4) 0.64
Cancer type
Lung 3 (23.1) 19 (41.3) 9 (16.1)
Bone marrow 7 (53.9) 1 (2.2) 10 (17.9)
Liver 1 (7.7) 3 (6.5) 2 (3.6)
Pancreas 1 (7.7) 2 (4.4) 4 (7.1) <0.01
Esophagus 0 6 (13.0) 2 (3.6)
Colon 1 (7.7) 1 (2.2) 3 (5.4)
Other* 0 1 (2.2) 10 (17.9)
Prior to Admission
Cancer diagnosis known 10 (76.9) 37 (80.4) 43 (76.8) 0.66
Living will completed 4 (30.8) 10 (21.7) 12 (21.4) 0.97
Health care proxy established
3 (23.1) 13 (28.3) 10 (17.9) 0.21
DNR established 2 (15.4) 8 (17.4) 17 (30.4) 0.04
Abbreviations: DNR, do not resuscitate.
*Other cancer types: rectal, stomach, bone sarcoma, renal cell, laryngeal, renal pelvic.
TABLE 3. Patient or Surrogate Participation in
End-of-Life Discussions, Treatments Received,
and Timing of Advanced Care Planning Among
Patients With Documented Decision-Making
Capacity on Admission
Patients With Documented
Decision-Making Capacity on
Admission (N ¼ 115)
End-of-Life
Discussion
With Surrogate
(N ¼46)
End-of-Life
Discussion
With Patient
(N ¼ 56)
N (%) N (%) P Value
Life-Prolonging Treatment
Ventilatory support 26 (56.5) 13 (23.2) <0.01
Chemotherapy 18 (39.1) 3 (5.4) <0.01
Artificial nutrition or hydration 21 (45.7) 14 (25.0) 0.03
Antibiotics 45 (97.8) 44 (78.6) <0.01
Cardiopulmonary resuscitation 7 (15.2) 4 (7.1) 0.19
ICU treatment (admit or transfer) 26 (56.5) 13 (23.2) <0.01
Palliative Treatments
Comfort care 39 (84.8) 45 (80.4) 0.56
Palliative morphine drip 24 (52.2) 33 (57.1) 0.62
Mean
(95% CI)
[Range]
Mean
(95% CI)
[Range]
Timing of Advanced Care Planning
Length of hospitalization 15.8 d (11.4–20.2) [1–57] 10.3 d (1–46) [1–46] 0.03
Time to end-of-life discussion 14.0 d (9.9–18.1) [0–55] 6.1 d (3.8–8.4) [0–46] <0.01
Time to comfort care 23.5 d (4.3–42.8) [1–374] 9.2 d (6.3–12.1) [0–46] 0.12
Abbreviations: CI, confidence interval; ICU, intensive care unit. *P value is for comparison of end-of-life dis-
cussion with surrogate vs end-of-life discussion with patient.
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patients who did not have a DNR order prior to
admission. The difference in life-prolonging treat-
ments between those who did and did not participate
in end-of-life discussions was preserved among those
patients who did not have DNR status on admission
(data not shown).
DISCUSSION
In this retrospective study of 145 terminal cancer
patients who died in the hospital, we found that half
of the patients had documentation suggesting that
they lost decisional capacity during hospitalization
and did not participate in end-of-life discussion with
their healthcare providers. Among cancer patients in
our study, 19% were determined not to have deci-
sional capacity on admission, and another 32% were
determined to lose decisional capacity during the
hospital course. When patients did participate in
documented discussions about end-of-life care, they
were less likely to receive intensive life-sustaining
treatments, less likely to be admitted or transferred to
the ICU, and more likely to avoid prolonged hospitali-
zation. The finding that the majority of cancer
patients are assessed to have intact decisional capacity
upon admission to their terminal hospitalization, but
less than half of them participate in their own end-of-
life conversation, suggests that there is an important
lost opportunity to provide quality advanced care
planning to hospitalized patients.
Advanced care planning is the act of defining a com-
petent patient’s wishes regarding their future health-
care in the event of loss of decisional capacity. For
many of the patients who were determined to lose
decisional capacity during their hospitalization in our
study, a surrogate decision-maker was involved in a
subsequent end-of-life discussion. This represents a
missed opportunity in 2 ways. First, because surro-
gates may incorrectly predict patients’ end-of-life
treatment preferences in approximately one-third of
the cases,25 patients may receive care that is inconsis-
tent with their beliefs. Second, reliance on surrogate
decision-making may result in a greater burden on
family members. Surrogate decision-making places a
large burden on surrogates, and can lead to emotional
and psychological stress that can last well beyond the
death of the loved one.16,26
Our results reinforce the growing body of evidence
suggesting that communication with the dying patient,
both before and during the terminal hospitalization,
promotes end-of-life care that involves less invasive
life-prolonging treatments,10–15 which is a consistently
stated goal of most patients at the end of life.1,2 Our
findings are consistent with a recent randomized trial
of hospitalized patients over the age of 80 which
showed that advance care planning discussions were
associated with decreased use of intensive life-sustain-
ing treatments, increased patient and family satisfac-
tion with care, as well as decreased psychological
symptoms among family members.27 In addition,
studies examining patients with advanced cancer have
shown that discussions about end-of-life care in the
outpatient setting resulted in less intensive life-sustain-
ing treatments.14,15 Nearly 20% of our cohort was
determined by the clinical team to lack decisional
capacity at the time of their terminal hospitalization,
highlighting the importance of end-of-life discussion
prior to hospitalization. Our results also extend these
recent findings to the inpatient setting. Seventy-nine
percent of patients in our study were determined to
have decisional capacity at the time of their terminal
hospitalization, and end-of-life discussion conducted
with these patients was associated with decreased use
of life-sustaining treatments.
Seriously ill patients, particularly in hospital settings,
have high symptom burden and subsequent poor qual-
ity of life.6 These patients and families often report
inadequate pain and symptom relief.8,28,29 It is there-
fore reassuring that we found no difference in the
proportion of patients who received comfort care and
palliative morphine infusions according to whether
they or a surrogate participated in the end-of-life dis-
cussions. In fact, the majority of patients were made
DNR and received some form of comfort measure
prior to death, although these comfort measures were
frequently initiated only hours prior to death.
While our findings are consistent with research that
has demonstrated that end-of-life discussions with
patients are associated with a decrease in life-pro-
longing treatments, it is important to note that our
observational study cannot establish a causal rela-
tionship between the end-of-life discussion and the
subsequent use of life-sustaining treatments. It is pos-
sible that patients who have discussions about end-
of-life care inherently prefer to have less intensive
life-sustaining treatment at the end of life. Physicians
may be more apt to engage in these types of discus-
sions with patients who express interest in limited
intervention. Interestingly, patients with a DNR
order at the time of admission were more likely to
participate in end-of-life care with their provider dur-
ing their terminal hospitalization, which supports
this alternate explanation. However, when we
excluded all patients with a DNR on admission, our
findings persisted. Regardless of the explanation for
the association between end-of-life discussions and
life-sustaining treatments, our study identifies a
cohort of hospitalized patients who could benefit
from improved end-of-life communication, and a
clinical setting where opportunities remain to
improve the quality of advanced care planning.
Discussions about end-of-life care with patients
result in earlier transition to care focused on pallia-
tion.14 Although we examined the timing to initiation
of comfort care between those who participated and
those who did not participate in end-of-life discus-
sions, we were not able to demonstrate a statistically
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significant difference. However, our cohort may not
be suitable for an examination of this type of inter-
vention, as early discussions about end-of-life care
may have lead to early referral to hospice, and there-
fore death outside the hospital setting, making the
patients ineligible for our study.
There are several additional limitations to our study.
First, our study is subject to the potential biases inher-
ent in retrospective chart review. For example, since
we identified patients who died in the hospital, our
study does not generalize to patients with advanced
cancer who survive the hospitalization or who were
discharged to die at home.30 Furthermore, our use of
the medical record to assess documentation of com-
munication about end-of-life care and decisional
capacity relies on the accuracy of clinician documenta-
tion. There may have been communication about
end-of-life care that was not documented in the medi-
cal record, resulting in underestimation of the effects
of end-of-life discussions. In clinical practice, the
assessment of decisional capacity can be challeng-
ing.19,31,32 Although clinicians are often accurate in
identifying patients with capacity, in nearly one-quar-
ter of all assessments, they mistakenly assign capacity
to patients who lack decision-making capacity.17 In
our study, we examine clinician assessment of the
patient’s decisional capacity, but cannot assess either
the accuracy of their clinical assessment or the accu-
racy of their documentation of this assessment. A
second limitation is that the chart abstraction was
conducted by a single reviewer without inter-rater
assessment, although the abstraction tool was modi-
fied from a well-established tool.24 A third limitation
is that all of the patients were from a single academic
center and the results may not generalize to other
regions. Fourth, we did not assess for the potential
effect of individual clinicians. Since most patients
were cared for by multiple physicians, our study is
not capable of assessing a clinician-level effect.
Finally, our study was not able to address whether the
care received by patients was in accord with their
informed preferences.
We have shown that opportunities exist for
advanced care planning at the time of the terminal
hospitalization of patients with advanced cancer. The
majority of these patients have documentation of deci-
sional capacity at the time of admission, suggesting
that opportunities exist to conduct end-of-life discus-
sion while the patient retains decisional capacity.
Furthermore, we found that patients who participate
in these discussions about end-of-life care with their
clinicians have an associated decrease in the use of
life-sustaining treatments, which is consistent with
prior studies.11,13–15,27 Improving communication
about end-of-life care for patients hospitalized with
advanced cancer may represent an important opportu-
nity to improve the concordance between patients’
wishes for care at the end-of-life and the care that
these patients actually receive. Such communication
may also decrease the burden on family members who
are frequently asked to play the role of surrogate
decision-maker without an opportunity to discuss
these issues with the patient.
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